Corporate Banner
Satellite Banner
Scientific Community
Join | Sign in

  News Archive

Promising Results of Phase 1/2 Trial of Rociletinib in EGFR Lung Cancer Published
Friday, May 08, 2015
Results have been published of a multi-center phase I/II study of the investigational anti-cancer agent rociletinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC) that had progressed after previous treatment with EGFR inhibitors.

Epilepsy Drug Metabolism Test Launched for Epilepsy and Seizure Disorders
Friday, May 08, 2015
Courtagen Life Sciences, Inc have announced the release of a NGS test focused on detection of anti-epileptic drug (AED) compatibilities and interactions for patients receiving treatment for epilepsy or other seizure disorders.

Supercooling May Aid Drug Delivery
Friday, May 08, 2015
A new study published is the first to break down the rules governing the complex process of crystallization through rapid-cooling.

Optivia and Hurel Form Technology and Marketing Alliance
Thursday, April 30, 2015
Firms partner to improve understanding of in vitro/in vivo correlation for transporter-mediated hepatic clearance, drug-drug interactions, and drug-induced liver injury.

Agilent Collaborate with National University of Singapore
Friday, April 24, 2015
Company to support NUS Medicine's research for safer, more effective medicine for heart disease.

Quotient Clinical Completes Innovative First-In-Human Program
Thursday, April 23, 2015
First-in-human clinical program designed to develop an optimal oral formulation.

XenoTech Plans Expansion to New Global Headquarters
Wednesday, April 22, 2015
The expansion will double the size of the global headquarters, providing space for an expanding range of services.

Pacific BioLabs Appoints VP Of Toxicology
Wednesday, April 22, 2015
Pacific BioLabs has appointed Michael Yakes, PhD as Vice President of Toxicology, responsible for all toxicology, PK/ADME, bioassay, and biocompatibility testing.

Neuropsychiatric Drug Candidate Shows Good Safety & Tolerability
Wednesday, April 08, 2015
Transition Therapeutics announces results from Phase 1 AME & renal clearance clinical studies of neuropsychiatric drug candidate ELND005.

<< 1 2 3 4 5 6 7 >>
Showing Results 11 - 20 of 2419
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters